Akebia Therapeutics logo
Akebia Therapeutics AKBA
$ 1.38 1.47%

Annual report 2025
added 02-26-2026

report update icon

Akebia Therapeutics Financial Statements 2011-2026 | AKBA

Annual Financial Statements Akebia Therapeutics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

334 M 274 M 257 M 141 M 358 M 479 M 892 M 669 M 653 M 370 M 194 M 158 M - - -

Shares

257 M 211 M 187 M 183 M 166 M 138 M 118 M 117 M 43.5 M 37.7 M 26.5 M 15.4 M - - -

Historical Prices

1.3 1.3 1.37 0.77 2.16 3.46 8.87 7.28 14.3 10 7.3 9.26 - - -

Net Income

-5.34 M -69.4 M -51.9 M -94.2 M -282 M -385 M -280 M -144 M -76.9 M -136 M -60.7 M -37 M -13.2 M -8.2 M -

Revenue

236 M 160 M 195 M 292 M 212 M 295 M 335 M 208 M 178 M 1.54 M - - - - -

Cost of Revenue

39.5 M 63.2 M 74.1 M 85.6 M 151 M 296 M 145 M 7.77 M - - - - - - -

Gross Profit

- - - - - - 190 M 200 M - - - - - - -

Operating Income

23.5 M -50.5 M -46.3 M -80.8 M -265 M -378 M -286 M -178 M -76.7 M -136 M -61.5 M -37.9 M -15.9 M -8.52 M -

Interest Expense

58 K 94 K 887 K 3.15 M 2.41 M 1.86 M -794 K 81 K 204 K -188 K 287 K 700 K -704 K -1.64 M -

EBITDA

24.8 M -49 M -44.7 M -79.1 M -263 M -376 M -248 M -176 M -79.3 M -136 M -61.4 M -37.9 M -14.9 M -8.52 M -

Operating Expenses

173 M 147 M 167 M 288 M 325 M 376 M 476 M 378 M 258 M 138 M 61.5 M 37.9 M - - -

General and Administrative Expenses

107 M 107 M 100 M 139 M 174 M 154 M 149 M 87.1 M 27 M 22.2 M 18.5 M 12.5 M 5.15 M 2.89 M -

All numbers in USD currency

Quarterly Income Statement Akebia Therapeutics

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

265 M 263 M 235 M 225 M 210 M 210 M 205 M 195 M 188 M 187 M 185 M 184 M 184 M 184 M 180 M 177 M 174 M 161 M 154 M 145 M 143 M 137 M 128 M 119 M 119 M 118 M 117 M 69.4 M 57 M 56.9 M 48.6 M 47.4 M 46.9 M 40.8 M 38.8 M 38.6 M 37.9 M 37.8 M 36.9 M 30.7 M 28.8 M 26.6 M 20 M 20.4 M 19.7 M 19.7 M 2.23 M 1.38 M 547 K 505 K 476 K - - - - - - - -

Net Income

540 K 247 K 6.11 M - -20 M -8.58 M -18 M - -14.5 M -11.2 M -26.2 M - -54.1 M 29.4 M -62.4 M - -59.5 M -83 M -69.6 M -87 M -60 M -176 M -60.7 M -94.5 M -54.6 M -58.2 M -72.4 M -60.1 M -26 M -34.1 M -60.1 M 15.5 M -23.1 M -21.5 M -44.5 M -37.9 M -36.3 M -35.8 M -25.8 M -19.9 M -19.5 M -10.7 M -10.7 M -10.4 M -9.35 M -7.62 M -9.7 M -5.95 M -3.77 M -2.83 M -621 K - - - - - - - -

Revenue

58.8 M 62.5 M 57.3 M - 37.4 M 43.6 M 32.6 M - 42 M 56.4 M 40.1 M - 48.7 M 126 M 61.7 M - 48.8 M 52.9 M 52.3 M - 60 M 90.1 M 88.5 M - 92 M 101 M 72.7 M - 53.2 M 48.8 M 45.9 M - 41.3 M 28.5 M - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

9.38 M 9.92 M 7.62 M - 14.2 M 17 M 11.6 M - 18 M 17.3 M 19.5 M - 38.3 M 18.6 M 31.3 M - 15.9 M 52.5 M 34.6 M 63.2 M 30.3 M 175 M 27.7 M 38.1 M 38.3 M 37.7 M 31.3 M 7.77 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

4.45 M 14.1 M 13.5 M - -12.5 M -8.72 M -14.9 M - -13 M -9 M -24.9 M - -50.4 M 34.1 M -58.5 M - -54.9 M -79.3 M -64.9 M -85.4 M -58.1 M -174 M -59.1 M -94.9 M -55.9 M -59.5 M -76 M -90.2 M -27.8 M -35.7 M -24.5 M 14.6 M -24.2 M -22.1 M -45 M -38 M -36.2 M -36.2 M -26 M -20 M -19.7 M -10.9 M -10.9 M -10.6 M -9.58 M -7.84 M -9.91 M -6.2 M -4.03 M -3.12 M -2.58 M - - - - - - - -

Interest Expense

-10 K -28 K 213 K - -17 K -39 K 95 K - -43 K -10 K 282 K - 1.17 M 411 K 1.13 M - 427 K 1.26 M 161 K - 410 K 376 K 350 K - -185 K 23 K -78 K - 16 K 32 K 4 K - 200 K 10 K -6 K - -345 K 139 K 14 K - 64 K 116 K 96 K - 56 K 51 K 19 K - 28 K 2.91 K -754 K - - - - - - - -

EBITDA

- - 13.8 M - -3.5 M 275 K -14.6 M - -4.04 M 4 K -15.9 M - -41.4 M 43.1 M -49.5 M - -45.9 M -70.3 M -55.9 M -85.4 M -57.6 M -173 M -58.6 M -94.9 M -55.3 M -58.9 M -75.5 M -90.2 M -27.2 M -35.2 M -24.3 M 14.6 M -23.8 M -21.9 M -44.8 M -38 M -36 M -36.1 M -26 M -20 M -19.6 M -10.8 M -10.9 M -10.6 M -9.57 M -7.83 M -9.9 M -6.2 M -4.03 M -3.12 M -2.58 M - - - - - - - -

Operating Expenses

44.9 M 38.5 M 36.2 M - 35.8 M 35.3 M 35.9 M - 37.1 M 48.1 M 45.6 M - 60.8 M 73.7 M 88.8 M - 87.7 M 79.8 M 82.6 M 78.9 M 87.7 M 89.3 M 120 M 126 M 110 M 123 M 117 M 142 M 81 M 84.5 M 70.4 M 75.9 M 65.5 M 50.7 M 65.8 M 39.6 M 36.2 M 36.2 M 26 M 20 M 19.7 M 10.9 M 10.9 M 10.6 M 9.58 M 7.84 M 9.91 M 6.2 M 4.03 M 3.12 M 2.58 M - - - - - - - -

General and Administrative Expenses

29.1 M 26.6 M 25.7 M - 26.5 M 26.9 M 25.4 M - 22.7 M 27 M 25.2 M - 31.9 M 32.2 M 44.3 M - 46.4 M 41.7 M 41.3 M - 40.2 M 35.5 M 38 M - 34.2 M 36.1 M 34.3 M - 10.4 M 12.5 M 9.02 M - 6.75 M 6.9 M 5.79 M - 4.94 M 5.31 M 5.81 M - 4.07 M 4.38 M 4.23 M - 2.94 M 2.32 M 3.75 M - 794 K 668 K 679 K - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Akebia Therapeutics AKBA
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Akebia Therapeutics plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 9.32 1.19 % $ 603 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.89 0.51 % $ 6.54 M chinaChina
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 22.48 1.26 % $ 3.73 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Innoviva Innoviva
INVA
$ 23.09 0.17 % $ 1.56 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
BioNTech SE BioNTech SE
BNTX
$ 104.34 2.72 % $ 27.2 B germanyGermany
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
$ 1.45 -2.03 % $ 235 M franceFrance
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.95 -1.34 % $ 4.86 M israelIsrael
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.08 0.74 % $ 436 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 22.96 2.64 % $ 2.92 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Edesa Biotech Edesa Biotech
EDSA
$ 15.11 -4.97 % $ 48.3 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.44 1.77 % $ 383 M britainBritain
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.76 -0.42 % $ 27.9 M israelIsrael
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Exelixis Exelixis
EXEL
$ 45.14 1.01 % $ 12.3 B usaUSA